Biotech | April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
It is one of the 15 medical device manufacturers approved under the government’s PLI scheme
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
One of the most advanced cancer care centres in the state of Odisha, it is equipped with the latest technology and a highly experienced multi-disciplinary team of oncologists
BVX-0922 to target colorectal cancer under investigator-sponsored IND
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Subscribe To Our Newsletter & Stay Updated
